SavedAdd your journal

Journals / European Journal of Life Sciences / 2026 / Volume: 4 Issue: 2

Synthetic strategies and biological screening of novel pyrazolines as COX inhibitors

Betül Kaya(BILECIK SEYH EDEBALI UNIVERSITY)0000-0002-1713-9485
Begüm Nurpelin Sağlık(ANADOLU UNIVERSITY)0000-0002-0151-6266
Yusuf Özkay(ANADOLU UNIVERSITY)0000-0001-5948-1855
Zafer Asım Kaplancıklı(Bilecik Şeyh Edebali University)0000-0003-2252-0923
Pages
—
Publication Date
2025-08-31
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These findings suggest that these compounds could be lead compounds for further development as selective COX-2 inhibitors.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this study, a novel series of pyrazolines was afforded by the reaction of 2-hydrazinyl-N-(4-aminosulfonylphenyl)acetamide (2) and chalcone intermediates.
📊
Key Findings & Data:The structures of target compounds were confirmed by IR, 1H NMR, 13C NMR and HRMS.
💡
Conclusion & Impact:These findings suggest that these compounds could be lead compounds for further development as selective COX-2 inhibitors.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Anti-inflammatory · COX-1 · COX-2

Abstract

In this study, a novel series of pyrazolines was afforded by the reaction of 2-hydrazinyl-N-(4-aminosulfonylphenyl)acetamide (2) and chalcone intermediates. The structures of target compounds were confirmed by IR, 1H NMR, 13C NMR and HRMS. The synthesized compounds were further evaluated for their in vitro COX inhibitory activity in order to discover new, effective and safer anti-inflammatory agents. Most of the compounds were more selective for COX-2 isozyme than COX-1. All compounds were weak inhibitors when compared to standard drugs ibuprofen, celecoxib and nimesulide. Among them, compounds 4a, 4e and 4f were the most potent inhibitors of COX-2. These findings suggest that these compounds could be lead compounds for further development as selective COX-2 inhibitors.

🔖

Cite This Article

Kaya, B., Sağlık, B. N., Özkay, Y., Kaplancıklı, Z. A. (2025). Synthetic strategies and biological screening of novel pyrazolines as COX inhibitors. European Journal of Life Sciences, Volume: 4 Issue: 2. https://doi.org/10.55971/EJLS.1712793

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (31)

  1. Reddy KK, Vidya Rajan VK, Gupta A, Aparoy P, Reddanna P. Exploration of binding site pattern in arachidonic acid metabolizing enzymes, cyclooxygenases and lipoxygenases. BMC Res Notes. (2015);8:152. https://doi.org/10.1186/s13104-015-1101-4
  2. Abdelgawad MA, Labib MB, Ali WAM, Kamel G, Azouz AA, EL-Nahass E. Design, synthesis, analgesic, anti-inflammatory activity of novel pyrazolones possessing aminosulfonyl pharmacophore as inhibitors of COX-2/5-LOX enzymes: histopathological and docking studies. Bioorg Chem. (2018);78:103–114. https://doi.org/10.1016/j.bioorg.2018.03.011
  3. Elgohary MK, Abo-Ashour MF, Abd El Hadi SR, El Hassab MA, Abo-El Fetoh M E, Afify H, Abdel-Aziz HA, Abou-Seri SM. Novel anti-inflammatory agents featuring phenoxy acetic acid moiety as a pharmacophore for selective COX-2 inhibitors: Synthesis, biological evaluation, histopathological examination and molecular modeling investigation. Bioorg Chem. (2024);152:107727. https://doi.org/10.1016/j.bioorg.2024.107727
  4. Ragab FAEF, Mohammed EI, Jaleel GAA, Abd El-Rahman AAM, Nissan YM. Synthesis of hydroxybenzofuranyl-pyrazolyl and hydroxyphenyl-pyrazolyl chalcones and their corresponding pyrazoline derivatives as COX inhibitors, anti-inflammatory and gastroprotective agents. Chem Pharm Bull. (2020);68(8):742-752. https://doi.org/10.1248/cpb.c20-00193
  5. Abdellatif KR, Abdelall EK, Elshemy HA, Lamie PF, Elnahaas E, Amin DM. Design, synthesis of new anti-inflammatory agents with a pyrazole core: COX-1/COX-2 inhibition assays, anti-inflammatory, ulcerogenic, histopathological, molecular modeling, and ADME studies. J Mol Struct. (2021);1240:130554. https://doi.org/10.1016/j.molstruc.2021.130554
  6. Perrone MG, Lofrumento DD, Vitale P, De Nuccio F, La Pesa V, Panella A, Calvello R, Cianciulli A, Panaro MA, Scilimati A. Selective cyclooxygenase-1 inhibition by P6 and gastrotoxicity: preliminary investigation. Pharmacology. (2015);95:22–28. https://doi.org/10.1159/000369826
  7. Wallace JL. Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy. World J Gastroenterol. (2013);19(12):1861–1876. https://doi.org/10.3748/wjg.v19.i12.1861
  8. Tanaka A, Hase S, Miyazawa T, Ohno R, Takeuchi K. Role of cyclooxygenase (COX)-1 and COX-2 inhibition in nonsteroidal anti-inflammatory drug-induced intestinal damage in rats: relation to various pathogenic events. J Pharmacol Exp Ther. (2002);303(3):1248–1254. https://doi.org/10.1124/jpet.102.041715
  9. Garcia-Rodriguez LA, Hern´ andez-Diaz S. Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs, Am J Med. (2001);110:20-27. https://doi.org/10.1016/s0002-9343(00)00682-3
  10. Ruan CH, So SP, Ruan KH. Inducible COX-2 dominates over COX-1 in prostacyclin biosynthesis: mechanisms of COX-2 inhibitor risk to heart disease, Life Sci. (2011);88:24–30. https://doi.org/10.1016/J.LFS.2010.10.017
  11. Hwang SH, Wecksler AT, Wagner K, Hammock BD. Rationally designed multitarget agents against inflammation and pain. Curr Med Chem. (2013);20(13):1783–1799. https://doi.org/10.2174/0929867311320130013
  12. Sun SX, Lee KY, Bertram CT, Goldstein JL. Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization. Curr Med Res Opin. (2007);23(8):1859-1866. https://doi.org/10.1185/030079907X210561
  13. Ghifari TA, Wulan FF, Astuti E, Suryanti V, Putri DEK, Nur H, Wahyuningsih TD. Synthesis of furan-based pyrazoline as an anticancer agent: an in vitro and in silico approach toward COX-2 inhibition. J Mol Struct. (2025);1337:142125. https://doi.org/10.1016/j.molstruc.2025.142125
  14. Ayman R, Abusaif MS, Radwan AM, Elmetwally AM, Ragab A. Development of novel pyrazole, imidazo [1, 2-b] pyrazole, and pyrazolo [1, 5-a] pyrimidine derivatives as a new class of COX-2 inhibitors with immunomodulatory potential. Eur J Med Chem. (2023);249:115138. https://doi.org/10.1016/j.ejmech.2023.115138
  15. Labib MB, Fayez AM, EL-Shaymaa EN, Awadallah M, Halim PA. Novel tetrazole-based selective COX-2 inhibitors: Design, synthesis, anti-inflammatory activity, evaluation of PGE2, TNF-α, IL-6 and histopathological study. Bioorg Chem. (2020);104:104308. https://doi.org/10.1016/j.bioorg.2020.104308
  16. Al-Turki DA, Al-Omar MA, Abou-Zeid LA, Shehata IA, Al-Awady MS. Design, synthesis, molecular modeling and biological evaluation of novel diaryl heterocyclic analogs as potential selective cyclooxygenase-2 (COX-2) inhibitors. Saudi Pharm J. (2017);25(1):59-69. https://doi.org/10.1016/j.jsps.2015.07.001
  17. Harras MF, Sabour R, Alkamali OM. Discovery of new non-acidic lonazolac analogues with COX-2 selectivity as potent anti-inflammatory agents. Med Chem Commun. (2019);10:1775–1788. https://doi.org/10.1039/C9MD00228F
  18. Nehra B, Rulhania S, Jaswal S, Kumar B, Singh G, Monga V. Recent advancements in the development of bioactive pyrazoline derivatives. Eur J Med Chem. (2020);205:112666. https://doi.org/10.1016/j.ejmech.2020.112666
  19. Abdel-Sayed MA, Bayomi SM, El-Sherbeny MA, Abdel-Aziz NI, ElTahir KEH, Shehatou GSG, Abdel-Aziz AA-M. Synthesis, antiinflammatory, analgesic, COX-1/2 inhibition activities and molecular docking study of pyrazoline derivatives. Bioorg Med Chem. (2016);24:2032-2042 https://doi.org/10.1016/j.bmc.2016.03.032
  20. Elgohary MK, Abd El Hadi SR, Abo-Ashour MF, Abo-El Fetoh ME, Afify H, Abdel-Aziz HA, Abou-Seri SM. Fragment merging approach for the design of thiazole/thiazolidine clubbed pyrazoline derivatives as anti-inflammatory agents: Synthesis, biopharmacological evaluation and molecular modeling studies. Bioorg Chem. (2023);139:106724. https://doi.org/10.1016/j.bioorg.2023.106724
  21. Mantzanidou M, Pontiki E, Hadjipavlou-Litina D. Pyrazoles and pyrazolines as anti-inflammatory agents. Molecules. (2021);26(11):3439-3457. https://doi.org/10.3390/molecules26113439
  22. Altintop MD, Temel HE, Özdemir A. Microwave-assisted synthesis of a series of 4, 5-dihydro-1H-pyrazoles endowed with selective COX-1 inhibitory potency. J Serb Chem Soc. (2023);88(4):355-365. https://doi.org/10.2298/JSC220907001A
  23. Raut DG, Lawand AS, Kadu VD, Hublikar MG, Patil SB, Bhosale DG, Bhosale RB. Synthesis of asymmetric thiazolyl pyrazolines as a potential antioxidant and anti-inflammatory agents. Polycycl Aromat Compd. (2020);42(1):70–79. https://doi.org/10.1080/10406638.2020.1716028
  24. Kharbanda C, Alam MS, Hamid H, Javed K, Bano S, Dhulap S, Ali Y, Nazreen S, Haider S. Synthesis and evaluation of pyrazolines bearing benzothiazole as anti-inflammatory agents. Bioorg Med Chem. (2014);22:5804–5812. https://doi.org/10.1016/j.bmc.2014.09.028
  25. Yan R, Huang X, Deng X, Song M. Synthesis and activity evaluation of some pyrazole–pyrazoline derivatives as dual anti-inflammatory and antimicrobial Agents. Polycycl Aromat Compd. (2021);42(8):5006–5019. https://doi.org/10.1080/10406638.2021.1919156
  26. Sihag M, Manuja A, Rani S, Soni R, Rani N, Malik S, Bhardwaj K, Kumar B, Kinger M, Miglani M, Aneja DK. Synthesis of pyrazole and pyrazoline derivatives of β-ionone: Exploring anti-inflammatory potential, cytotoxicity, and molecular docking insights. Eur J Med Chem Rep. (2024);12:100204. https://doi.org/10.1016/j.ejmcr.2024.100204
  27. Thach TD, Nguyen TMT, Nguyen TAT, Dang CH, Luong TB, Dang VS, Banh KS, Luc VS, Nguyen TD. Synthesis and antimicrobial, antiproliferative and anti-inflammatory activities of novel 1, 3, 5-substituted pyrazoline sulphonamides. Arab J Chem. (2021);14(11):103408. https://doi.org/10.1016/j.arabjc.2021.103408
  28. Kaya Çavuşoğlu B, Sağlık BN, Acar Cevik U, Osmaniye D, Levent S, Özkay Y, Kaplancıklı ZA. Design, synthesis, biological evaluation, and docking studies of some novel chalcones as selective COX‐2 inhibitors. Arch Pharm. (2021);354(3):2000273. https://doi.org/10.1002/ardp.202000273
  29. Biovision COX‐1 Fluorescent Inhibitor Screening Kit (Catalog No: K548‐100) manual, http://www.biovision.com/manuals/K548.pdf
  30. Biovision COX‐2 Fluorescent Inhibitor Screening Kit (Catalog No:K547‐100) manual, http://www.biovision.com/manuals/K547.pdf
  31. Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. (2017);7:42717. https://doi.org/10.1038/srep42717